Global High Content Screening Products Market: Snapshot
Keen players in the global high content screening products market
are pouring money into research and development of new technologically
advanced instruments that would help the cause of designing new
therapies for different ailments. In this manner they are trying to
bolster their positions in the market. They are also resorting to
mergers and acquisitions to expand their geographical outreach. Since
the degree of competition in the global high content screening products
market is relatively low at present, many aspiring players are planning
to foray into it.
Increasing thrust on cell-based research,
various initiatives to develop new drugs, and emergence of more
sophisticated image analysis instruments are some of the factors that
are serving to drive the global high-content screening (HCS) market. The
increasing instances of chronic diseases requiring prolonged treatment
such as HIV AIDS, epilepsy and Parkinson’s disease along with the
growing requirement of determination and study of toxicity levels in the
initial phases of drug discovery is also bolstering the market.
Research organizations, pharmaceutical
and biotechnology companies, and academic and research institutes are
the end-use segments in the global high content screening products
market.
As per Transparency Market Research, the
global high content screening products market will likely rise at a CAGR
of 8.0% from 2017 to 2022 to become worth US$1.23 bn by 2022.
Cost Effectiveness of High Screening Instruments Generates Demand in Market
Depending upon the type of products, the
global high content screening products market can be segmented into
consumables, microplates, instruments, software, and service. The
consumables, among them, hold maximum market share at present. By
expanding at a CAGR of 8.3% in the forecast period, the segment will
become worth US$486.6 mn in 2022. The high screening instruments too
account for a substantial share in the market because of their cost
efficiency that results from deployment of LED light engines that brings
down the intensity fluctuations and hence negates the need to switch to
external illuminating sources.
High content screening software will
likely grow at a healthy clip in the foreseeable future in the global
high content screening market because of features such as confocal
imaging and intuitive workflow interface. This helps to bring about
development of three dimensional models allowing better evaluation,
increased sensitivity precise image capture, and analyzation of more
parameters which is predicted to generate more demand in the market in
the upcoming years.
Prevalence of Chronic Diseases Drives North America Market to Fore
From a geographical standpoint, North
America leads the global high content screening market on the back of
increasing prevalence of chronic diseases, a considerable population of
elderly, rising collaborations of research institutes,
carefully-considered mergers and acquisitions between companies, and an
advanced healthcare infrastructure. The market in the region is
predicted to clock a healthy 8.2% CAGR between 2017 and 2022. Rising at
this pace it is expected to attain a value of US$402.1 mn in 2022.
Europe follows North America vis-à-vis
revenue generation in the global high content screening products market.
It currently accounts for 25.8% revenue share in the global high
content screening products market. This is mainly because of the
substantial investments in healthcare and government regulations in the
region. Vis-à-vis growth rate, Asia Pacific is projected to outpace all
other regions. By the end of 2022, Japan high content screening products
market is projected to reach US$113.1 mn, by registering a CAGR of 7.8%
over the forecast period.
Global High Content Screening Market: Competitive Analysis
Some of the prominent participants in the
global high content screening products market are Thermo Fisher
Scientific, Molecular Devices, GE Healthcare, PerkinElmer Inc., Becton,
Dickinson and Company, Thorlabs, Inc., Merck KGaA, Cell Signaling
Technology, Genedata AG, and Yokogawa Electric Corporation.
No comments:
Post a Comment